The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Background The widespread use of Immune checkpoint-inhibitors (ICI) has revolutionised
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …

Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically
up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is …

Simple Summary Immunotherapy-based combinations represent the front-line standard of
care for metastatic clear cell renal cell carcinoma (mccRCC) patients. These combinations …

Background Patient survival in advanced/metastatic melanoma, non‐small cell lung cancer
(NSCLC), and renal cell carcinoma (RCC) has improved with immune checkpoint inhibitors …

Background: Although VEGFR tyrosine kinase inhibitors (TKIs) are a preferred systemic
treatment approach for patients with advanced renal cell carcinoma (RCC) and thyroid …

Renal cancer is the seventh most common cancer in men and the tenth in women. The aim
of this article is to review the diagnosis, treatment, and follow-up of renal carcinoma …

Background: Over the past few years, significant advancements have been achieved in the
front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will …

Background and objectives Investigations of the prognosis are vital for better patient
management and decision-making in patients with advanced metastatic renal cell …

Introduction While there are a plethora of studies supporting novel treatment approaches in
metastatic clear cell renal cell carcinoma (ccRCC), much of the data used to inform care of …